Le Lézard
Classified in: Health
Subjects: BFA, FVT

Allergan Aesthetics Announces First Ever JUVÉDERM® Day


The Number One Chosen Dermal Filler Collection Celebrates with Exclusive Offers 

IRVINE, Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration recognizes the aesthetics providers and patients who have made the JUVÉDERM® Collection of Fillers the number one chosen* collection of dermal fillers in the U.S.1 JUVÉDERM® Day provides both new and loyal consumers savings and exclusive offers through All?, the Allergan Aesthetics loyalty program.

"To celebrate the first ever JUVÉDERM® Day, we wanted to do something special, which is why we're offering consumers this first-of-its-kind promotion," said Jasson W. Gilmore, Senior Vice President, Allergan Data Labs at Allergan Aesthetics. "JUVÉDERM® Day provides an opportunity to encourage consumers to take advantage of special offers and book a consultation with an aesthetic specialist. It is also a chance to celebrate the accomplishments of a brand that has revolutionized the dermal filler category with scientifically proven products and positive results."

Consumers interested in participating in JUVÉDERM® Day are encouraged to join All? to take advantage of exciting offers. These offers include:

The exclusive BOGO gift card and Triple Take offers are available to both new and existing All? Members. Terms and Conditions apply. To join All?, visit alle.com.

"I am thrilled to celebrate the first ever JUVÉDERM® Day with my patients! I have trusted and utilized the JUVÉDERM® Collection of Fillers for more than a decade," said Dr. Anna Guanche, Board-Certified Dermatologist. "The breadth of JUVÉDERM® products in the collection enables me to provide each patient with a customized approach based on their unique needs and anatomy.2-7 JUVÉDERM® Day gives patients who are interested in trying JUVÉDERM® for the first time a great opportunity to speak with their aesthetic specialist to determine which product in the JUVÉDERM® Collection of Fillers may be right for them."

The JUVÉDERM® Collection of Fillers currently offers six specially formulated, modified hyaluronic acid (HA) fillers to address patients' varying facial treatment needs: JUVÉDERM® VOLUMA® XC, JUVÉDERM® VOLBELLA® XC, JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, JUVÉDERM® VOLUX® XC.2-7 The safety and efficacy of the JUVÉDERM® Collection of Fillers has been demonstrated in more than 330 clinical studies.8 Patients who are interested in HA fillers should schedule a consultation with their aesthetic specialist to see if they're a candidate and discuss a treatment plan customized to their desired outcome.

Consumers and new patients who receive aesthetic treatment from the Allergan Aesthetics portfolio of products can also enroll in All?, the Allergan Aesthetics loyalty rewards program, to unlock access to curated content, exclusive offers, and personalized rewards that can be used for savings on the Allergan Aesthetics portfolio of products and redeemed at a participating provider's office, subject to applicable program terms and conditions. All? is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 40 non-Allergan Aesthetics treatments and brands.

Recognized by National Day Archives as an official holiday on the National Day Registrytm, JUVÉDERM® Day will be held annually on the third Wednesday of August.

For more information on the JUVÉDERM® Collection of Fillers, visit Juvederm.com and follow @JUVÉDERM on Instagram and TikTok.

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit AllerganAesthetics.com.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas ? immunology, oncology, neuroscience, and eye care ? and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn

JUVÉDERM® Injectable Gel Fillers Important Information

APPROVED USES

JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 21.

JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.

JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 21.

JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 21.

JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

Are there any reasons why I should not receive any JUVÉDERM® formulation?
Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.

What warnings should my doctor advise me about?

What precautions should my doctor advise me about?

What are possible side effects of treatment?
The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. 

These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).

As with all skin injection procedures, there is a risk of infection.

To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1?877?345?5372. Please also visit Juvederm.com or talk to your doctor for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

* Based on a March 2023 Provider Survey Data (N=953)1 

References:

  1. Data on File, Allergan; Dermal Filler AMT, March 2023.
  2. JUVÉDERM® VOLUMA® XC Patient Labeling, 2020.
  3. JUVÉDERM® VOLBELLA® XC Patient Labeling, 2021.
  4. JUVÉDERM® Ultra XC Patient Labeling, 2020.
  5. JUVÉDERM® Ultra Plus XC Patient Labelling, 2020.
  6. JUVÉDERM® VOLLURE® XC Patient Labelling, 2020.
  7. JUVÉDERM® VOLUX® XC Patient Labeling, 2022.
  8. Data on file, Allergan; Number of Allergan product publications, July 20, 2022.  

© 2023 AbbVie. All rights reserved. JUVÉDERM and its designs are trademarks of Allergan Holdings France SAS, and AbbVie company, or its affiliates. All other trademarks are property of their respective owners.

 

SOURCE AbbVie


These press releases may also interest you

at 17:10
The global aronia berries market size is estimated to grow by USD 501.5 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 9.64% during the forecast period. Health benefits of aronia berries is driving...

at 17:09
Every senior deserves to age in health, in safety and in dignity. Everyone should have the choice to age at home, in their communities, on their terms. That includes 2SLGBTQI+ Canadians. However, many 2SLGBTQI+ seniors do not have all of the supports...

at 17:00
VITALHUB CORP.   (the "Company" or "VitalHub") today reported a summary of the voting results of its Annual General and Special Meeting of Shareholders (the "Meeting"). Results of the Meeting The Company is reporting the voting results of its...

at 17:00
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary DiffuSpheretm technology to optimize drug delivery...

at 16:59
Dr. Bill Lippy, an internationally recognized physician and philanthropist, passed away June 29, 2024 surrounded by his loving family. Dr. Lippy, was born in Niles, Ohio in 1928. After graduating from Oberlin College, Lippy completed...

at 16:40
The global ambulance services market  size is estimated to grow by USD 13.74 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.79%  during the forecast period.  Increasing number of road accidents is...



News published on and distributed by: